Abstract: Purpose: To study the effect of inflammatory markers in blood such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) on the Gleason score (GS) changes in patients with prostate cancer (PCa) after radical prostatectomy (RP), we conducted this study.
Patients and Methods: From November 2012 to September 2021, a total of 237 patients underwent RP at our institution. Blood samples from all patients were collected within 1 week before surgery. Preoperative clinical characteristics include age, serum IL-6 and TNF-α, neutrophil-to-lymphocyte ratio, C-reactive protein, the platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, systemic immune-inflammation index, the prostate imaging reporting and data system (PI-RADS) score, prostate-specific antigen, and biopsy GS were assessed. Univariate and multivariate logistic regression analyzes were used to determine the risk factors of GS changes after RP. The efficiency of this prediction model was identified with the area under the curve of the receiver operating characteristic curve.
Results: Seventy-three patients (30.8%) had GS upgraded in the overall cohort, and 55 patients (23.2%) had GS downgraded. In comparing PCa patients with and without GS upgraded, multivariate logistic regression analysis showed that serum TNF-α (odds ratio [OR]: 2.518, p = 0.019) and IL-6 (OR: 0.478, p = 0.023) were independent factors predicting the occurrence of GS upgrade. We also compared the characteristics of patients with GS upgraded and GS downgraded; multivariate logistic regression analysis also demonstrated significant differences in serum IL-6 and TNF-α between these two groups (all p < 0.05). In addition, we found that low prostate volume and biopsy GS ≥ 7 were significantly associated with higher PI-RADS sores in multivariate analysis.
Conclusion: The high expression of serum TNF-α level is positively correlated with GS upgraded in PCa patients. High expression of serum IL-6 level is negatively correlated with GS upgraded in PCa patients and positively related with GS downgraded.
(© 2022 Wiley Periodicals LLC.)
References: Henley SJ, Ward EM, Scott S, et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer. 2020;126(10):2225-2249.
Schroder FH, Hugosson J, Roobol MJ, et al. The European randomized study of screening for prostate cancer-prostate cancer mortality at 13 years of follow-up. Lancet. 2014;384(9959):2027-2035.
Verep S, Erdem S, Ozluk Y, Kilicaslan I, Sanli O, Ozcan F. The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: how safe is it to depend on bioptic pathology? Prostate. 2019;79:1523-1529.
Vellekoop A, Loeb S, Folkvaljon Y, Stattin P. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer. J Urol. 2014;191(2):350-357.
Kaye DR, Qi J, Morgan TM, et al. Pathological upgrading at radical prostatectomy for patients with grade group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance. BJU Int. 2019;123(5):846-853.
Wang K, Karin M. Tumor-elicited inflammation and colorectal cancer. Adv Cancer Res. 2015;128:173-196.
Lin W, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117(5):1175-1183.
Hurwitz LM, Kulac I, Gumuskaya B, et al. Use of aspirin and statins about inflammation in benign prostate tissue in the placebo arm of the prostate cancer prevention trial. Cancer Prev Res. 2020;13(10):853-862.
Aglamis E, Ceylan C, Akin MM. Is there a correlation between the aggressiveness of chronic asymptomatic prostatitis National Institutes of Health category IV and the Gleason score in patients with prostate cancer? Can Urol Assoc J. 2020;14(11):E568-E573.
Banzola I, Mengus C, Wyler S, et al. Expression of indoleamine 2,3-dioxygenase induced by IFN-γ and TNF-α as potential biomarker of prostate cancer progression. Front Immunol. 2018;9:1051.
Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin 6 (IL-6). BJU Int. 2014;113(6):986-992.
Chadha KC, Miller A, Nair BB, Schwartz SA, Trump DL, Underwood W. New serum biomarkers for prostate cancer diagnosis. Clin Cancer Investig J. 2014;4(1):72-79.
Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer. 2004;90(12):2312-2316.
Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2-science direct. Eur Urol. 2019;76(3):340-351.
Swanson GP, Trevathan S, Hammonds K, Speights VO, Hermans MR. Gleason score evolution and the effect on prostate cancer outcomes. Am J Clin Path. 2020;155(5):711-717.
Jo JK, Hong SK, Byun SS, Lee SE, Lee S, Oh JJ. Prognostic significance of the disparity between biopsy and pathologic Gleason score after radical prostatectomy in clinical candidates for active surveillance according to the royal marsden criteria. Clin Genitourin Cancer. 2016;14(4):e329-e333.
Sarici H, Telli O, Yigitbasi O, et al. Predictors of Gleason score upgrading in patients with prostate biopsy Gleason score ≤6. Can Urol Assoc J. 2014;8(5-6):E342-E346.
Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol. 2018;199(3):683-690.
Murata M. Inflammation and cancer. Environ Health Prev Med. 2018;23(1):50.
Nowroozi MR, Ayati M, Amini E, et al. Role of chronic inflammation as a predictor of upstaging/upgrading in prostate cancer: finding a new group eligible for active surveillance. Urol J. 2020;17(4):370-373.
Sanguedolce F, Falagario UG, Castellan P, et al. Bioptic intraprostatic chronic inflammation predicts adverse pathology at radical prostatectomy in patients with low-grade prostate cancer. Urol Oncol. 2020;38(10):719-793.
Zhai L, Fan Y, Sun S, et al. PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer. Scand J Urol. 2018;52(5-6):333-339.
Processing Request
No Comments.